Altimmune, Inc.

Thank you for standing by. This is the conference operator. Welcome to the Altimmune, Inc. First Quarter 2020 Earnings Conference Call. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. To join the question queue, you may press star then 1 on your telephone keypad. Should you need assistance during the conference call, you may signal an operator by pressing star and zero. I would now like to turn the conference over to Monique Kosas of LifeSci Advisors. Please go ahead. Thank you, operator.

And thank you, everyone, for participating in today's first quarter 2020 earnings conference call. Leading the way today will be Stephen Gard, Chief Executive Officer of Altimmune. Also participating on the call today is Will Brown, Chief Financial Officer, Scott Roberts, Chief Scientific Officer, and Scott Harris, Chief Medical Officer. After the prepared remarks, we will open up the call for a question and answer session. A press release with the first quarter 2020 financial results was issued last night and can be found on the investor's page of the company's website. Before we begin, I would like to remind everyone that remarks about future expectations, plans, and prospects constitute forward-looking statements for the purpose of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Ultimate cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including those related to COVID-19 and its impact on our business operations, clinical trials, and results of operations. For a discussion of some of the risk factors that could affect the company's future results, please see the risk factors and other cautionary statements contained in the company's filings with the Securities and Exchange Commission. I would also direct you to read the forward-looking statement disclaimer in our earnings release issued last night and now available on our website. Any statements made on this conference call speak only as of today's date, Thursday, May 14, 2020, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today's date. As a reminder, this conference call is being recorded and will be available for audio rebroadcast on Altamune's website at www.altamune.com. With that, I will now turn the call over to Vipin Garg, Chief Executive Officer of Altamune. Vipin, please go ahead.

Thank you, Monique. Good morning, everyone, and thank you for joining us as we discuss our Q1 2020 financial results. and Corporate Update. Joining me on the call today is Bill Brown, our Chief Financial Officer, who will review our Q1 financial results, as well as Scott Harris, our Chief Medical Officer, and Scott Roberts, our Chief Scientific Officer. After our discussion, we will open the call for Q&A. We have all watched in recent months the historic impact of COVID-19 on both our businesses and our personal lives. Our thoughts and prayers go out to all of those fighting this disease, including both our healthcare workers and those infected. Most of our employees continue to work remotely, with the exception of our lab personnel, who continue their important COVID-19 vaccine development work. Despite operating under these conditions, we have made significant strides this year to advance our development programs. and today we will be providing you an update on our progress both on our vaccine and our liver disease product candidates. We advanced our COVID-19 vaccine candidate, ADCOVID, into preclinical testing at the University of Alabama at Birmingham. This is an important milestone for this program as we continue to be hopeful that our COVID-19 vaccine candidate will have a significant impact on the disease. believe the attributes of our platform technology are ideally suited for a pandemic. And as a confirmation, the World Health Organization published a target product profile for an ideal COVID-19 vaccine candidate that closely aligns with the clinically proven profile of our vaccine technology. Namely, a single dose, non-injectable vaccine that can be shipped without refrigeration and provides a rapid and long-lasting immunity. Regarding NasoShield, our anthrax vaccine program, we anticipate starting our Phase 1b trial next month. NasoShield, like all of our vaccine candidates, is designed as a single-dose, Thank you very much. continue to advance ALT801, our GLP-1 glucagon dual agonist, to work the clinic with our IND-enabling studies and product manufacturing. We are very excited about the potential of this program. In a head-to-head comparison of our compound in the preeminent mouse model, we saw more than double the weight loss compared to semaglutide and greater improvement in histological measures of fatty liver Liver Inflammation, and Fibrosis. This is important as Novo Nordisk recently announced their successful phase two trial where they met their primary endpoint of resolution of NASH and no worsening of fibrosis. However, we believe that Alt-80-1 can do better and has the potential to achieve best in class profile, not only for GLP-1 derived therapeutics, but NASH drugs as a whole. Finally, we have completed the manufacturing activities of hep T cell and are finalizing the IND, which we expect to file next week. The planned trial is a six-month course of treatment in chronically infected hepatitis B patients with clinical sites in the US, Canada, and Europe. As disclosed in the press release, we will wait to initiate this study until the impact of COVID-19 on the trial can be better understood. I would now like to turn the call over to Scot Roberts, our Chief Scientific Officer, who will fully update you on the progress we have made with AdCOVID, then Scot Harris, who will discuss our clinical plans for Alt-801 and NasoShield. Scot?